MoonLake Immunotherapeutics
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$227.3M
- Total assets
- $424.4M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $244.8M
- Operating income
- -$244.8M
- Income tax
- $611.0K
- Net income
- -$230.3M
- EPS (basic)
- $-3.53
- EPS (diluted)
- $-3.53
Balance sheet
- Total assets
- $424.4M
- Current assets
- $421.7M
- Total liabilities
- $120.0M
- Current liabilities
- $45.5M
- Shareholders’ equity
- $304.5M
Cash flow
- Operating cash flow
- -$196.0M
- Investing cash flow
- $203.0M
- Financing cash flow
- $146.0M
- Net cash flow
- $153.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-3.53
- Shares outstanding
- 73.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 6, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $227.3M.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MoonLake Immunotherapeutics.
Write a review
News about MoonLake Immunotherapeutics
News & sentiment via Polygon.io
